Flexion Therapeutics
Flexion Therapeutics is a biopharmaceutical company that specializes in the development and commercialization of novel, local therapies. The company's primary focus is on the treatment of musculoskeletal conditions, particularly osteoarthritis.
History[edit | edit source]
Founded in 2007, Flexion Therapeutics is headquartered in Burlington, Massachusetts. The company was established with the aim of developing innovative and sustained therapies for diseases affecting the musculoskeletal system.
Products[edit | edit source]
Flexion Therapeutics' flagship product is Zilretta (triamcinolone acetonide extended-release injectable suspension), which is the first and only FDA-approved extended-release, intra-articular therapy for patients confronting osteoarthritis-related knee pain. Zilretta employs proprietary microsphere technology combining triamcinolone acetonide — a commonly administered, short-acting corticosteroid — with a poly lactic-co-glycolic acid (PLGA) matrix.
Research and Development[edit | edit source]
Flexion Therapeutics is committed to ongoing research and development in the field of musculoskeletal conditions. The company is currently investigating the potential of FX201, a gene therapy candidate for the treatment of osteoarthritis.
See Also[edit | edit source]
References[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD